• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

1例经贝伐单抗注射治疗的眼部良性淋巴组织增生症

A case of ocular benign lymphoid hyperplasia treated with bevacizumab injection.

作者信息

Oh Doo Hwan, Chun Yeoun Sook, Kim Jae Chan

机构信息

Department of Ophthalmology, Chung-Ang University College of Medicine, Seoul, Korea.

出版信息

Korean J Ophthalmol. 2011 Feb;25(1):57-9. doi: 10.3341/kjo.2011.25.1.57. Epub 2011 Jan 17.

DOI:10.3341/kjo.2011.25.1.57
PMID:21350697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3039197/
Abstract

We report the first case of ocular benign lymphoid hyperplasia (BLH) treated with subconjunctival injection of bevacizumab (Avastin). A 27-year-old man presented to our clinic with conjunctival masses and limbal neovascularization. An incisional biopsy yielded the diagnosis of BLH. The patient was subsequently given a subconjunctival injection of bevacizumab (1.25 mg / 0.1 mL). The patient did not experience recurrence or malignant metaplasia during the one-year follow-up period. In patients with conjunctival BLH, subconjunctival injection of bevacizumab can be a useful treatment option in patients unable to undergo a surgical procedure due to limbal neovascularization.

摘要

我们报告了首例采用贝伐单抗（阿瓦斯汀）结膜下注射治疗的眼部良性淋巴组织增生症（BLH）。一名27岁男性因结膜肿物和角膜缘新生血管来到我们诊所。切开活检确诊为BLH。随后该患者接受了贝伐单抗结膜下注射（1.25毫克/0.1毫升）。在一年的随访期内，患者未出现复发或恶性化生。对于患有结膜BLH且因角膜缘新生血管而无法接受手术的患者，结膜下注射贝伐单抗可能是一种有效的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c2/3039197/63bea7e7d6a4/kjo-25-57-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c2/3039197/1a450c200124/kjo-25-57-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c2/3039197/63bea7e7d6a4/kjo-25-57-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c2/3039197/1a450c200124/kjo-25-57-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8c2/3039197/63bea7e7d6a4/kjo-25-57-g002.jpg

相似文献

1
A case of ocular benign lymphoid hyperplasia treated with bevacizumab injection.1例经贝伐单抗注射治疗的眼部良性淋巴组织增生症
Korean J Ophthalmol. 2011 Feb;25(1):57-9. doi: 10.3341/kjo.2011.25.1.57. Epub 2011 Jan 17.
2
Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.局部应用贝伐单抗滴眼液治疗即将复发的翼状胬肉的角膜缘-结膜新生血管化
Cornea. 2009 Jan;28(1):103-4. doi: 10.1097/ICO.0b013e3181822615.
3
Successful Treatment of Conjunctival Lymphangiectasia With Subconjunctival Injection of Bevacizumab.结膜下注射贝伐单抗成功治疗结膜淋巴管扩张症
Cornea. 2016 Oct;35(10):1375-7. doi: 10.1097/ICO.0000000000000899.
4
Regression of iris neovascularization after subconjunctival injection of bevacizumab.结膜下注射贝伐单抗后虹膜新生血管的消退
Korean J Ophthalmol. 2013 Aug;27(4):299-303. doi: 10.3341/kjo.2013.27.4.299. Epub 2013 Jul 18.
5
The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.早期和晚期贝伐单抗（阿瓦斯汀）注射抑制兔角膜缘不全的角膜新生血管和结膜化的不同作用。
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6277-85. doi: 10.1167/iovs.09-4571. Epub 2010 Apr 30.
6
The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.结膜下注射不同剂量贝伐单抗对角膜新生血管的影响。
Int Ophthalmol. 2013 Oct;33(5):507-13. doi: 10.1007/s10792-013-9732-8. Epub 2013 Feb 13.
7
Subconjunctival bevacizumab injection for ocular surface squamous neoplasia.眼表面鳞状上皮肿瘤的结膜下bevacizumab 注射。
Cornea. 2013 Jul;32(7):998-1001. doi: 10.1097/ICO.0b013e318289ddd8.
8
Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.在不同的角膜新生血管兔模型中结膜下注射贝伐单抗（阿瓦斯汀）对角膜新生血管的影响
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1659-65. doi: 10.1167/iovs.08-1997. Epub 2008 Nov 7.
9
Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up.结膜自体移植联合结膜下注射贝伐单抗治疗原发性翼状胬肉的随机对照试验：1年随访
Clin Exp Ophthalmol. 2014 Apr;42(3):235-41. doi: 10.1111/ceo.12140. Epub 2013 Jul 5.
10
Vascular changes after intra-bleb injection of bevacizumab.在房水渗漏区注射贝伐单抗后的血管变化。
J Glaucoma. 2008 Oct-Nov;17(7):517-8. doi: 10.1097/IJG.0b013e31815f5345.

引用本文的文献

1
Local chemotherapy with conjunctival bevacizumab injections in case of lymphoma tumor.淋巴瘤肿瘤病例中采用结膜注射贝伐单抗进行局部化疗。
Rep Pract Oncol Radiother. 2024 Dec 4;29(5):661-665. doi: 10.5603/rpor.102880. eCollection 2024.
2
Bilateral benign reactive lymphoid hyperplasia of the conjunctiva: a case treated with oral doxycycline and review of the literature.双侧结膜良性反应性淋巴组织增生症：1例口服强力霉素治疗病例及文献复习
Eye Vis (Lond). 2019 Sep 2;6:26. doi: 10.1186/s40662-019-0151-4. eCollection 2019.

本文引用的文献

1
Topical bevacizumab therapy for corneal neovascularization.局部应用贝伐单抗治疗角膜新生血管。
Arch Ophthalmol. 2007 Jun;125(6):834-6. doi: 10.1001/archopht.125.6.834.
2
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.贝伐单抗作为炎症性角膜血管生成和淋巴管生成的强效抑制剂。
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2545-52. doi: 10.1167/iovs.06-0570.
3
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).贝伐单抗（阿瓦斯汀）对实验性角膜新生血管形成的抑制作用
Br J Ophthalmol. 2007 Jun;91(6):804-7. doi: 10.1136/bjo.2006.107912. Epub 2006 Dec 19.
4
Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).玻璃体内注射贝伐单抗（阿瓦斯汀）治疗糖尿病性视网膜病变中的持续性新生血管（IBEPE研究）
Retina. 2006 Nov-Dec;26(9):1006-13. doi: 10.1097/01.iae.0000246884.76018.63.
5
Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗年龄相关性黄斑变性继发的轻微典型性和隐匿性脉络膜新生血管。
Graefes Arch Clin Exp Ophthalmol. 2007 Jan;245(1):68-73. doi: 10.1007/s00417-006-0466-4. Epub 2006 Nov 18.
6
A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.一种使用新型抗血管内皮生长因子（VEGF）药物抑制角膜新生血管形成的潜在治疗策略。
Med Hypotheses. 2007;68(4):799-801. doi: 10.1016/j.mehy.2006.06.063. Epub 2006 Nov 14.
7
Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.血管内皮生长因子-a促进肿瘤周围淋巴管生成和淋巴转移。
Cancer Res. 2005 Oct 15;65(20):9261-8. doi: 10.1158/0008-5472.CAN-04-2345.
8
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.贝伐单抗（阿瓦斯汀），一种用于癌症治疗的人源化抗血管内皮生长因子单克隆抗体。
Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35. doi: 10.1016/j.bbrc.2005.05.132.
9
Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling.在肌动蛋白解聚因子突变小鼠中，自发性角膜血管生成和淋巴管生成依赖于血管内皮生长因子受体3信号传导。
Am J Pathol. 2005 May;166(5):1367-77. doi: 10.1016/S0002-9440(10)62355-3.
10
Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.通过中和血管内皮生长因子（VEGF）抑制正常风险角膜移植后的血管生成和淋巴管生成可促进移植物存活。
Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2666-73. doi: 10.1167/iovs.03-1380.